General information about U.S. regulatory definitions and published research, not legal, medical, or manufacturing advice.

"Custom peptide company" describes a business model, not a regulatory status. Making a peptide to order is a chemistry problem with a well-documented answer. Selling one is a statutory problem with a much less forgiving one: the same molecule can be a drug, a biologic, or an unapprovable product depending on length, intended use, and who receives it. Below is a primary-sourced map of what U.S. law asks of the company itself — registration, labeling, recordkeeping, documentation, and penalties.

What is a custom peptide company?

A custom peptide company synthesizes a peptide to a sequence the customer specifies rather than selling only stock items. The method is almost always solid-phase peptide synthesis (SPPS), which Merrifield introduced in 1963 before building the first automated peptide synthesizer in 1965; he also established that coupling efficiency must exceed 99% per step for SPPS to succeed, per a 2022 review in *Frontiers in Chemistry*. That same review notes the length reliably achievable on automated synthesizers "is generally limited to be less than 50 amino acids," with RP-HPLC as the standard purification method.

Platform choice sets throughput. Standard Fmoc SPPS protocols take roughly 60–100 minutes per residue, while flow-based synthesis incorporates a residue every ~1.8 minutes automated (3 minutes manual), with amide bond formation "99.9% complete in less than 2 minutes," per a 2014 report in *ChemBioChem*.

Where does a peptide company's product line stop being a peptide?

At 40 amino acids. FDA defines "protein" as "any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size" (21 C.F.R. § 600.3), so a synthetic peptide of 40 or fewer residues is regulated as a drug, not a biologic. FDA set that numeric bright line in a final rule published February 21, 2020 at 85 FR 10057, effective March 23, 2020, choosing a residue count over structural or functional criteria because those "would not provide regulatory certainty."

Cross the line and the regime changes entirely. "Protein" is expressly listed in the statutory definition of a biological product, and no person may introduce a biological product into interstate commerce without a biologics license, under 42 U.S.C. § 262(a)(1)(A) and (i)(1).

Does a custom peptide company have to register with FDA?

If it makes drugs, yes — and selling "research" peptides does not avoid it. Every owner or operator of an establishment "engaged in the manufacture, preparation, propagation, compounding, or processing of a drug" must register with FDA between October 1 and December 31 each year and list the drugs it makes for commercial distribution, under 21 U.S.C. § 360.

The research exemption is narrower than it is usually described. It reaches only those who make drugs "solely for use in research, teaching, or chemical analysis and not for sale" (21 U.S.C. § 360(g)(3); 21 C.F.R. § 207.13(e)). Those last four words do the work: a company whose business is selling research peptides is not within the exemption, whatever its catalog says.

Is it legal for a custom peptide company to sell peptides?

Start with how approval actually works, because the mechanism answers the question better than a flat assertion does. FDA approval attaches to a specific drug product through an application, not to a molecule or a category of molecules. 21 U.S.C. § 355(a) bars any new drug from interstate commerce unless an application filed under that section "is effective with respect to such drug," and § 355(b)(1) makes that application product-specific: it must cover the particular article's components, its full composition, the methods used in its manufacture, processing, and packing, and specimens of its proposed labeling. A peptide synthesized to order has no such application standing behind it, which is why "our peptide is the same molecule as an approved drug" is not an approval claim — approval never ran to the molecule in the first place.

Whether a given vial *is* a drug turns on intended use rather than chemistry: the FD&C Act's drug definition reaches "articles (other than food) intended to affect the structure or any function of the body of man or other animals" (21 U.S.C. § 321(g)(1)(C)).

"Intended use" means the seller's objective intent, and it is provable from "labeling claims, advertising matter, or oral or written statements," from the article's "design or composition," and from "the circumstances surrounding the distribution of the article" (21 C.F.R. § 201.128). Reclassification is not an exit either — a substance authorized for investigation as a new drug, where substantial clinical investigations have been instituted and made public, is excluded from the definition of a dietary supplement if it was not marketed as a supplement or food beforehand (21 U.S.C. § 321(ff)(3)(B)).

Does a "research use only" label protect the seller?

Partly, and only on its own terms — which are specific and include duties most catalogs never mention. A drug shipped for investigational use in laboratory research animals or in vitro tests must bear this exact caution: "CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans." That is 21 C.F.R. § 312.160, and the same section obliges the shipper to exercise "due diligence to assure that the consignee is regularly engaged in conducting such tests," and to keep records of recipient name, address, shipment date, quantity, and batch or code marks for two years after shipment, available to FDA on inspection.

A parallel rule limits what can be said. A sponsor, investigator, or anyone acting on their behalf "shall not represent in a promotional context that an investigational new drug is safe or effective… or otherwise promote the drug" (21 C.F.R. § 312.7(a)).

Can a custom peptide company supply compounding pharmacies?

For peptides specifically, the § 503A door is nearly closed. Compounding under 21 U.S.C. § 353a(a)–(b) must be done by a licensed pharmacist or licensed physician on a valid prescription order "for an identified individual patient," using bulk substances that meet a USP or NF monograph, are components of approved drugs, or appear on FDA's list — made by an FDA-registered establishment and accompanied by valid certificates of analysis. The same section bars compounding "regularly or in inordinate amounts" products that are "essentially copies of a commercially available drug product," and caps out-of-state distribution at 5 percent of total prescription orders absent a state memorandum of understanding with FDA.

The codified list is the bottleneck: 21 C.F.R. § 216.23 contains six substances — Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide (the last five topical use only) — and none is a peptide; four nominated substances (oxitriptan, piracetam, silver protein mild, tranilast) are expressly excluded. That regulation also states there are "inadequate data to demonstrate the safety or efficacy" of products compounded with listed substances, and that calling such a product "FDA approved" renders it misbranded.

That list has been under active pressure, and it is where vendor claims most often outrun the record. FDA announced a Pharmacy Compounding Advisory Committee meeting for July 23–24, 2026 to discuss nominated peptide bulk drug substances — among them BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, and Epitalon — in a meeting notice published at 91 FR. Read that document for what it is. A notice of meeting announces an agenda; it cannot report a result, and any indication of use attached to a nominated substance in such a notice reflects what the nomination proposed, not an FDA finding about the substance. As of this article's publication on August 12, 2026, no committee recommendation or resulting FDA action on those nominations had been published, and § 216.23 still lists the same six non-peptide substances. A vendor pointing at that meeting as proof its peptide is now compoundable is pointing at an agenda, not a rule. Separately, FDA's January 7, 2025 interim-policy notice "ends the categorization of bulk drug substances into Categories 1, 2, or 3 for those bulk drug substances nominated on or after the date of publication of this guidance," moving to rolling evaluation.

The § 503B route has different mechanics, not looser ones. An outsourcing facility "is not required to be a licensed pharmacy" and "may or may not obtain prescriptions for identified individual patients," but must register with FDA each October 1–December 31, report its products twice yearly (June and December), and may not use a bulk drug substance unless it is on FDA's clinical-need list or the drug appears on the § 356e shortage list (21 U.S.C. § 353b).

What documentation should you demand from a custom peptide company?

An impurity profile, not an adjective. FDA's synthetic-peptide guidance requires applicants to "identify and describe all peptide impurities present at a concentration greater than 0.10% of the API in the final drug product," as quoted in a 2024 study in *Frontiers in Pharmacology*. The threshold is that low for a reason: synthesis-derived impurities include amino acid insertions, duplications, deletions, and racemization plus side-chain oxidation and deamidation, and they can introduce new T-cell epitopes absent from the original API. In that salmon calcitonin (SCT) work, "the selected SCT variants induced immune responses" in donors who did not respond to SCT itself at an equivalent concentration — meaning the impurity, not the intended peptide, was what the immune system saw.

Regulators approach this as measurable work. FDA supplied 34 synthetic teriparatide impurities for immunogenicity evaluation in a 2025 generic-peptide risk assessment in *Frontiers in Immunology* using in silico, MHC-binding, and human T-cell assays. And in the guidance covering ANDAs for five highly purified synthetic peptides — glucagon, liraglutide, nesiritide, teriparatide, and teduglutide — FDA said the ANDA-versus-NDA question "will depend largely on the impurity profile for the synthetic peptide drug product as compared to the impurity profile for the peptide drug product of rDNA origin" (82 FR 46075).

Manufacturing controls carry their own standard: 21 C.F.R. § 211.1 sets "the minimum current good manufacturing practice for preparation of drug products… for administration to humans or animals," and a drug is adulterated if "the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to… current good manufacturing practice" (21 U.S.C. § 351(a)(2)(B)).

So the practical test of a supplier is documentary, not rhetorical: ask for the impurity profile and the analytical data behind it, and read what comes back against the 0.10% figure rather than against the adjectives on the label. Browse the Cornerstone Peptide catalog, where each item is listed with its stated identity and analytical documentation — the same standard this section asks you to apply to any vendor, this one included.

What legal exposure does a custom peptide company carry?

Criminal, with defined ceilings. Introducing an adulterated or misbranded drug into interstate commerce, or introducing a drug in violation of § 355, is a prohibited act under 21 U.S.C. § 331(a) and (d). A drug is misbranded if "its labeling is false or misleading in any particular," or if it lacks "adequate directions for use" and adequate warnings (21 U.S.C. § 352(a), (f)). A first § 331 violation carries up to 1 year imprisonment or a $1,000 fine; a violation after a prior conviction, or one committed "with the intent to defraud or mislead," carries up to 3 years or $10,000 (21 U.S.C. § 333(a)(1)–(2)).

One product category is far steeper. Knowingly distributing, or possessing with intent to distribute, human growth hormone — defined as "somatrem, somatropin, or an analogue of either of them" — "for any use in humans other than the treatment of a disease or other recognized medical condition, where such use has been authorized by the Secretary of Health and Human Services under section 355 of this title and pursuant to the order of a physician," carries up to 5 years imprisonment, rising to 10 years if the offense involves someone under 18 (21 U.S.C. § 333(e)). Note what that clause requires stacked together: an authorized use, for a recognized medical condition, on a physician's order. A research-use disclaimer satisfies none of the three. Prescription status matters too: a drug unsafe except under practitioner supervision must be dispensed only on prescription and must bear the symbol "Rx only," and dispensing contrary to that provision is itself "an act which results in the drug being misbranded while held for sale" (21 U.S.C. § 353(b)(1), (b)(4)(A)).

Frequently asked questions

What is a custom peptide company? A company that synthesizes peptides to customer-specified sequences, typically by solid-phase peptide synthesis with RP-HPLC purification; automated synthesizers reliably handle sequences of fewer than 50 amino acids, per a 2022 review in *Frontiers in Chemistry*.

Does a custom peptide company have to register with FDA? A drug-processing establishment must register between October 1 and December 31 each year, and the research exemption covers only drugs made "solely for use in research, teaching, or chemical analysis and not for sale" (21 U.S.C. § 360).

Does a "research use only" label protect the seller? Only on its own terms: 21 C.F.R. § 312.160 requires the exact caution ending "Not for use in humans," due diligence that the consignee is regularly engaged in such tests, and two years of shipment records available on inspection.

Are custom peptides FDA-approved? No, and the reason is structural: approval attaches to a specific product through an application, not to a molecule. No new drug may enter interstate commerce unless an application is effective with respect to that drug (21 U.S.C. § 355(a)), and intended use is judged from labeling, advertising, statements, design, and distribution circumstances (21 C.F.R. § 201.128).

Can a peptide company supply § 503A compounders? Rarely as the rule is written: the codified bulks list at 21 C.F.R. § 216.23 holds six substances and none is a peptide. FDA noticed a Pharmacy Compounding Advisory Committee meeting for July 23–24, 2026 on nominated peptides (91 FR), but no recommendation or resulting action had been published as of August 12, 2026.

What impurity documentation should a peptide company have? Every impurity above 0.10% of the API identified and described, per FDA's synthetic-peptide guidance as quoted in a 2024 *Frontiers in Pharmacology* immunogenicity study.

What is the steepest penalty a peptide seller faces? The human growth hormone provision. Knowingly distributing hGH for a use in humans outside an authorized treatment of a disease or other recognized medical condition, on a physician's order, carries up to 5 years' imprisonment — 10 if the offense involves someone under 18 (21 U.S.C. § 333(e)).